The selection of an appropriate opioid analgesic for ambulatory surgery carries meaningful clinical and economic implications. Among the agents most commonly evaluated in this context, remifentanil vs. fentanyl analgesia offer distinct pharmacological profiles that shape intraoperative management, recovery trajectories, and postoperative outcomes. While fentanyl has long served as the standard of care due to its low cost and ease of administration, the introduction of remifentanil has prompted a reexamination of opioid strategy for ambulatory surgery.
Fentanyl’s widespread use in ambulatory anesthesia is largely attributable to practical advantages: it is inexpensive, requires no continuous infusion setup, and is familiar to most anesthesiologists. In contrast, remifentanil is metabolized by nonspecific plasma and tissue esterases, yielding a terminal half-life of 8–20 minutes and a context-sensitive half-time of approximately three minutes. This pharmacokinetic property confers a highly predictable and titratable analgesic effect, making it theoretically well-suited to procedures requiring precise and rapid control.
The hemodynamic advantages of remifentanil have been demonstrated at scale. In a large multicenter, randomized, single-blind effectiveness trial enrolling 2,438 patients across 156 hospitals and ambulatory surgery facilities, remifentanil-treated patients exhibited greater intraoperative hemodynamic stability compared to fentanyl-treated patients, with hemodynamic effects that included lower intraoperative systolic and diastolic blood pressures and heart rates. Anesthesiologists perceived remifentanil as superior regarding their ability to predict responses and titrate. Outpatients in the remifentanil group also responded to verbal command earlier and were eligible for home discharge sooner than their fentanyl-treated counterparts, which is a significant benefit in ambulatory surgery (Twersky et al., 2001).
However, remifentanil was associated with a significantly higher incidence of intraoperative hypotension compared to fentanyl—12% versus 4% across all patients, with rates of 18% versus 7% in the inpatient subset. All four reported cases of muscle rigidity occurred exclusively in remifentanil-treated outpatients. Importantly, rates of respiratory depression, bradycardia, hypertension, and postoperative nausea and vomiting were broadly comparable between the two agents, suggesting that the overall adverse effect burden is manageable when appropriate dosing protocols are observed (Joshi et al., 2002).
The cost-effectiveness of remifentanil versus fentanyl in ambulatory practice is an important factor to consider. In a small prospective, double-blinded, randomized trial of 34 patients undergoing outpatient gynecologic laparoscopy or hysteroscopy, remifentanil offered no statistically significant improvement in recovery times, postoperative pain scores, or patient satisfaction when compared to fentanyl. Despite modest savings in sevoflurane consumption attributable to remifentanil’s opioid-sparing effects, total perioperative drug costs per patient were $17.74 higher in the remifentanil group, driven primarily by the higher drug acquisition cost of remifentanil and the increased expense of antiemetic treatment. The remifentanil group also experienced a significantly greater incidence of postoperative nausea that required rescue antiemetic therapy—a finding likely related to the administration of a supplemental longer-acting opioid near the end of the procedure to bridge the analgesic gap created by remifentanil’s rapid offset (Beers et al., 2000).
Taken together, these findings suggest that remifentanil offers distinct intraoperative advantages—particularly in hemodynamic stability and emergence quality—that may be of value in high-risk outpatients or procedures demanding precise opioid titration. Nevertheless, its routine use in ambulatory surgery is not uniformly cost-effective, and its rapid offset necessitates deliberate postoperative analgesic planning to avoid rebound pain and increased antiemetic requirements. Clinicians must weigh the pharmacokinetic advantages of remifentanil against its higher acquisition cost and the additional clinical management its use entails, tailoring opioid selection to the individual patient, procedural context, and institutional resources.
References
Beers, R. A., Calimlim, J. R., Uddoh, E., Esposito, B. F., & Camporesi, E. M. (2000). A comparison of the cost-effectiveness of remifentanil versus fentanyl as an adjuvant to general anesthesia for outpatient gynecologic surgery. Anesthesia & Analgesia, 91(6), 1420–1425. https://pubmed.ncbi.nlm.nih.gov/11093992/
Joshi, G. P., Warner, D. S., Twersky, R. S., & Fleisher, L. A. (2002). A comparison of the remifentanil and fentanyl adverse effect profile in a multicenter phase IV study. Journal of Clinical Anesthesia, 14(7), 494–499. https://pubmed.ncbi.nlm.nih.gov/12477583/
Twersky, R. S., Jamerson, B., Warner, D. S., Fleisher, L. A., & Hogue, S. (2001). Hemodynamics and emergence profile of remifentanil versus fentanyl prospectively compared in a large population of surgical patients. Journal of Clinical Anesthesia, 13(6), 407–416. https://pubmed.ncbi.nlm.nih.gov/11578883/